Pages
- Become a Site Champion
- Becoming a client
- Blog
- Canadian Investigators
- Cancer Patients
- Careers
- Contact Us
- Events & Conferences
- Home
- Newsroom
- Oncology Experience
- Our Company
- Our Team
- Phase 3 Oncology Clinical Trial Expertise
- Podcasts
- Privacy Policy
- Resource Library
- Reverse Feasibility Champions Award
- Reverse Feasibility Program
- Sitemap
- Small & Mid-Sized Biopharma
- Thanks you !
Posts by category
- Category: Accelerated Site Start-Up
- Some Facts About Canada… Mitigate COVID-19 Impact on Your Clinical Trials
- Smaller CROs May Do It Better, Quicker – Especially in Times of Crisis
- Consider This Region for Your Phase 3 Global Trial
- Recommendations for Quicker CTA Negotiation
- Overcome Today’s New Enrollment Challenges
- Collaborative Vendor Teaming for Better Oncology Trial Results – Real World Evidence
- Overcome Oncology Clinical Trial Obstacles – 2019 Real World Evidence for 2020 and Beyond
- Going Above-and-Beyond – What Can Your Specialized Oncology CRO Do for You?
- Oncology Trial Investigators and Participants – Where to Look?
- Hassle-Free Site Selection and Study Start-up for Clinical Trials in Canada
- Do You Believe the Myths About Conducting Clinical Trials in Canada?
- What is Most Important When Conducting Oncology Clinical Research in Canada?
- Your Specialized Oncology CRO as Strategic Advisor – Real World Evidence
- What to Look for When Selecting a CRO – Real World Evidence
- 2018 in Retrospect – Real World Evidence of Win-Win CRO/Sponsor Relationships
- 7 Tips for Efficient Oncology Study Start-up
- Real World Evidence of a Successful Oncology Trial Rescue in Canada
- How Does Your CRO’s Feasibility Process Contribute to Your Clinical Trial Success?
- Canadian Know-How: Successfully Navigating a Centralized Framework for Oncology Clinical Trial Ethical Review
- Canada: a Region of Choice for Your Study Expansion
- Why Does Your CRO’s Assignment Practice for CRAs Matter?
- Does Your Monitoring Vendor Hold the Key to Improving the Quality of Your Database?
- Will Canada’s Multi-Center Approval Processes Help Your Oncology Clinical Trial Exceed Pivotal Milestones?
- Exploring a ‘Rescue’ Strategy for Your Oncology Clinical Trial?
- Effectively Integrating a Regionally Specialized CRO Team into Your Existing US/Global Study Framework
- 20 Years of Unparalleled Canadian Oncology Clinical Research Experience
- Navigating Canadian Regulations for Oncology Clinical Research – Part I
- ‘5 step’ fail proof strategy to effective Clinical Trial Agreement Negotiations part 2
- ‘5 step’ fail proof strategy to effective Clinical Trial Agreement Negotiations part 1
- Accelerate Start-up for Oncology Clinical Trials through Centralized Ethics Review
- Centralized Ethics Review for Oncology Trials in Canada – An interview with Janet Manzo, Executive Director, Ontario Cancer Research Ethics Board
- Proven Approach to Site Selection is Attracting More Cutting-Edge Oncology Trials to Canada
- Leveraging Canada For Quicker Oncology Site Start-Up
- How to Start-Up 9 Oncology Sites in 9 weeks
- The Secret to Oncology Clinical Trial Performance – An Interview with Denise Deakin
- Top 5 Questions asked by Directors of Clinical Operations
- Overcoming Site Challenges in Oncology Trials – An interview with Penny Chipman
- Reponse to Questions Raised Over Canadian Oversight Of Clinical Trials
- Number of sites needed for a Phase 1A Oncology study
- Oncology drug reimbursement climate in Canada
- Reverse Feasibility in Action – Transcript of interview with Dr. Quincy Chu
- Value of Canadian oncology centers for early phase trials – Transcript of interview with Dr. Stephen Welch
- How to double your oncology enrolment targets
- How to speed up site start-up by 50%: Part 2 – Contract Negotiation
- How to speed up site start-up by 50% Step 1: Reverse Feasibility Approach
- Category: Big Data in Healthcare
- Category: Centralized Ethics Review
- Category: COVID-19 Series
- Category: Data Mining
- Category: Early Phase Clinical Trials
- Do Data Entry Issues & Backlog Threaten Your Clinical Trial?
- How Do CRAs Proactively Manage Risk with These Soft Skills?
- Daffodils & Cancer Research – what’s the connection?
- Julie’s advice: Conducting oncology clinical research in Canada
- Clinical Trial Agreements no longer a bottleneck for study site activation
- Oncology Clinical Operations in Canada
- Busting Myths about the Canadian Regulatory Review Process – An interview with Susanne Picard
- Importance of Strategic Advisors & Strong Leadership
- Importance of having a visionary drug development plan
- First Essential Asset for Successful Oncology Drug Development
- Why Canada is well suited for YOUR oncology clinical trials
- Quality, Speed & Performance – Keys to Canada’s Future – Interview with Karen Arts of the Ontario Institute for Cancer Research
- Value of Canadian Oncology Centers for Early Phase Trials – Interview with Dr. Stephen Welch
- Category: FAQs
- Category: General
- Looking for Key Clinical Trial Vendor Management Strategies?
- Impact of Clinical Trials on Cancer Patient Outcomes
- The Role of Patient Input for Oncology Drug Review – An Interview with CEO of the Canadian Cancer Action Network
- ‘Site’ vs. ‘Trial’ CRA assignments and why it matters
- Tips on developing oncology biomarkers and companion diagnostics – Transcript of interview with Dr. John Reddington
- Patients are the KEY Stakeholders in Clinical Trials
- Introducing the Scimega Oncology Blog!
- Category: Investigative Site Selection
- Category: Micro-patient Populations
- Category: Oncology Trials in Canada
- Category: Patient Advocacy
- Category: Personalized Medicine
- Category: Regulatory Affairs
- Category: Targeted Therapies
- Category: Technology in Clinical Trials
- Category: Uncategorized
Assets & Events
- Clinical Operations in Oncology Trials
East Coast 2020 - 2020 ASCO ANNUAL MEETING
- AACR Annual Meeting
2020 - Clinical Operations in Oncology Trials
West Coast 2020 - Key Strategies You Must Know to Survive in Today’s World of Oncology Clinical Research
- Phase Ib Antibody Drug Conjugate Study in Advanced Platinum-Resistant Ovarian Cancer
- Phase I/II Targeted Therapeutic Study in Advanced Colorectal Cancer
- Phase III Immuno-Oncology study in Advanced Renal Cell Carcinoma
- Phase I/II Advanced HER2+ Breast Cancer Study
- Reverse Feasibility in Action
- Guide to Accelerating Site Start-Up by 50%
- Clinical Cancer Advances 2015
- Canadian Cancer Stats 2015
- AACR Cancer Progress Report 2015
- The Secret to Oncology Clinical Trial Performance
- Busting Myths about Canadian Regulatory Review
- Centralized Ethics Review for Oncology Trials in Canada
- Benefits of Big Data Analytics in Oncology Clinical Research
- Biomarkers & Companion Diagnostics in Oncology Clinical Research
- Quality, Speed & Performance – Key Attributes to Canada’s Oncology Clinical Trial Future
- Role of Patient Input for Oncology Drug Reviews
- Early Warning Signs: An Ailing Canary in the Mine
- Reflections on Medical Oncology: 25 Years of Clinical Trials – Where Have We Come and Where Are We Going?
- Is Investigative Site Feasibility Feasible?
- Key Factors in CRO Selection
- Selecting the Right Outsourcing Providers for Your Oncology Clinical Trials
- Oncology Clinical Development Challenges & Opportunities in the Phase I Setting
- Personalized Medicine: How will the end of one-size-fits-all medicine affect the clinical trial industry?
- Ten Trends Transforming the Business of Oncology
- Tapping the Expertise of Oncology CROs
- Oncology Trial Comparator Drug Reimbursement: A Canadian Perspective
- Key Strategies You Must Know to Survive in Today’s World of Oncology Clinical Research
- Controlling The Known Variables – Strategies for solving the operational challenges of oncology clinical trials
- What Your CRO Doesn’t Know Could Hurt You – How to leverage Canada for Study Expansion & Recruitment
- A Word From Dr. Stephen Welch – A Reverse Feasibility Champion
- Optimizing North America For Your Oncology Trials
- Canadian Expansion from a Site’s Perspective
- The Secret to Unlocking the True Recruitment Potential of Canada
- The Reverse Feasibility Program Explained
- Value of Canadian Oncology Centers for Early Phase Trials